TY - JOUR
T1 - FUNCTIONAL IMMUNOPHENOTYPING FOR PRECISION THERAPIES IN SEPSIS
AU - Rao, Mahil
AU - Mcgonagill, Patrick W.
AU - Brackenridge, Scott
AU - Remy, Kenneth E.
AU - Caldwell, Charles C.
AU - Hotchkiss, Richard S.
AU - Moldawer, Lyle L.
AU - Griffith, Thomas S.
AU - Badovinac, Vladimir P.
N1 - Publisher Copyright:
Copyright © 2024 by the Shock Society.
PY - 2025/2/1
Y1 - 2025/2/1
N2 - Sepsis remains a significant cause of morbidity and mortality worldwide. Although many more patients are surviving the acute event, a substantial number enters a state of persistent inflammation and immunosuppression, rendering them more vulnerable to infections. Modulating the host immune response has been a focus of sepsis research for the past 50 years, yet novel therapies have been few and far between. Although many septic patients have similar clinical phenotypes, pathways affected by the septic event differ not only between individuals but also within an individual over the course of illness. These differences ultimately impact overall immune function and response to treatment. Defining the immune state, or endotype, of an individual is critical to understanding which patients will respond to a particular therapy. In this review, we highlight current approaches to define the immune endotype and propose that these technologies may be used to "prescreen"individuals to determine which therapies are most likely to be beneficial.
AB - Sepsis remains a significant cause of morbidity and mortality worldwide. Although many more patients are surviving the acute event, a substantial number enters a state of persistent inflammation and immunosuppression, rendering them more vulnerable to infections. Modulating the host immune response has been a focus of sepsis research for the past 50 years, yet novel therapies have been few and far between. Although many septic patients have similar clinical phenotypes, pathways affected by the septic event differ not only between individuals but also within an individual over the course of illness. These differences ultimately impact overall immune function and response to treatment. Defining the immune state, or endotype, of an individual is critical to understanding which patients will respond to a particular therapy. In this review, we highlight current approaches to define the immune endotype and propose that these technologies may be used to "prescreen"individuals to determine which therapies are most likely to be beneficial.
KW - ELISA
KW - Immunoparalysis
KW - elispot
KW - endotype
KW - flow cytometry
KW - hyperinflammation
UR - http://www.scopus.com/inward/record.url?scp=85211009898&partnerID=8YFLogxK
U2 - 10.1097/SHK.0000000000002511
DO - 10.1097/SHK.0000000000002511
M3 - Article
C2 - 39617419
AN - SCOPUS:85211009898
SN - 1073-2322
VL - 63
SP - 189
EP - 201
JO - Shock
JF - Shock
IS - 2
ER -